Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Dr. Cherag Daruwala of Hunterdon Gastroenterology Named 2021 NJ Top Doc


SCOTCH PLAINS, N.J., Jan.27, 2022 /PRNewswire-PRWeb/ -- NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2021. This is Dr. Daruwala's sixth consecutive year being reviewed and approved by NJ Top Docs. Dr. Daruwala is a board certified Gastroenterologist and Hepatologist.

After completing his fellowship in Gastroenterology, Dr. Daruwala went on to complete training in endoscopic ultrasound and was on staff at Temple University Hospital for 3 years prior to joining Hunterdon Gastroenterology Associates in 2012. Dr. Daruwala established the endoscopic ultrasound program at Hunterdon Medical Center.

"Like many gastroenterologists, I enjoy the technological aspect of my specialty. However, I am also receptive to patients who prefer a more holistic approach to treatment," says Dr. Daruwala.

Dr Daruwala is among the first gastroenterologists to offer Endoscopic Ultrasound in Central New Jersey. This procedure offers an accurate and less invasive method for the diagnosis and staging of various cancers. In addition to Endoscopic ultrasound, he has a keen interest in colon cancer screening as well as the management of acid reflux disease, hepatitis and irritable bowel syndrome. He has offices in Flemington and Somerville, New Jersey.

To learn more about Dr. Cherag Daruwala, please visit: https://njtopdocs.com/nj-doctors/daruwala/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

Media Contact

Marissa Pane, NJ Top Docs, 908-288-7240, [email protected]

Twitter

 

SOURCE NJ Top Docs


These press releases may also interest you

at 15:00
TELUS Health 2024 Drug Trends Report: Diabetes medications maintain top reimbursed expense position; ADHD drugs surge
TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30. Diabetes medications remain the leading drug category for eligible private...

at 14:45
Samuel Rodgers Health Center embracing safe seated mammography powered by Enable Me; U.S. trend toward seated exams benefits patients and technologists
With safe seated mammography trending in the U.S., the Samuel U. Rodgers Health Center (Sam Rodgers) reports its use of the Danish made VELA Mammography Chair has provided significant physical benefits for patients, health benefits for mammographers,...

at 14:35
MD Logic Health® and Liz Wolfe Unveil Revolutionary Collaboration with Daily Aminos+
MD Logic Health® is excited to announce a groundbreaking partnership with renowned Nutritional Therapy Practitioner, Liz Wolfe, to launch an innovative new supplement, Daily Aminos+. This collaboration combines MD Logic Health®'s expertise in...

at 14:34
Work-Life Referral Services Exempt from Taxes, Elevating Employee Wellbeing Through Caregiving Benefits Like Mellie
Last week, the Internal Revenue Service (IRS) issued a groundbreaking announcement on the tax treatment of work-life referral services provided to employees under an employer's work-life referral program. This development marks a significant...

at 14:30
Summer Health Announces Series A Fundraise from 7wireVentures and Lux Capital
Summer Health, a digital health company offering 24/7 pediatric support to parents, announced $11.65M in Series A Funding, co-led by new investor 7wire Ventures and returning investor Lux Capital. Returning investors Sequoia Capital, Metrodora...

at 13:56
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patientsGastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that...

More news about Health...


News published on and distributed by: